کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3258555 | 1207462 | 2006 | 12 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: B cell depletion therapy in systemic rheumatic diseases: Different strokes for different folks? B cell depletion therapy in systemic rheumatic diseases: Different strokes for different folks?](/preview/png/3258555.png)
Autoantibodies have, until recently, been the overriding focus of investigators of autoantibody-associated diseases. Increasing attention is now being paid to B cells, which not only are the producers of autoantibodies but also contribute to autoimmune disease via autoantibody-independent mechanisms. Therapeutic measures that target B cells for depletion are gaining in popularity. In this review, we will focus on two distinct approaches of depleting B cells; one employing a direct-kill approach by engagement of B cell surface CD20 with an anti-CD20 monoclonal antibody (rituximab), and the other employing an indirect starvation approach by neutralization of B lymphocyte stimulator (BLyS), a potent B cell survival factor. Among the systemic immune-based rheumatic disorders, we will focus on rheumatoid arthritis and systemic lupus erythematosus, two disorders for which therapeutic B cell targeting is being intensely investigated.
Journal: Clinical Immunology - Volume 121, Issue 1, October 2006, Pages 1–12